Background: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results: The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.
A 54-year-old patient presented with two types of pain. The first was similar to trigeminal neuralgia and the second was similar to cluster headache. Clinical diagnosis was cluster-tic syndrome. Neuro-imaging studies disclosed an ectatic basilar artery. The significance of this finding is difficult to ascertain.
Background: Lung cancer remains as the leading cause of cancer-related deaths worldwide, with non-small cell carcinoma (NSCLC) being the most frequent histology (85%). Therapies that target activating EGFR mutations are NSCLC first-line treatments that improve patient life expectancy and quality of life. However, despite the current availability of novel TKI drugs in Chile and other Latin-Americans countries, little is known about the molecular epidemiology of EGFR mutations in the region. In particular, Latin American patients are still largely under-represented in genomics databases or clinical trials for this disease. We are presenting the results of a large NGS-based screening of the NSCLC EGFR mutations in Chilean patients. The study is aimed at describing the prevalence of specific somatic actionable mutations, within this population and correlated data with relevant clinical and tumor aspects such as gender, age, specific histology, smoking habits, progression stage and co-occurrencewith KRAS mutations and other mutations. Method: Non-small cell lung cancer FFPE samples from 821 subjects, part of the non-interventional clinical study NIRVANA (NCT03220230), were sequenced using Oncomine Focus Assay (Thermo Fisher Scientific), which covers the most frequent and actionable EGFR mutations through nine amplicons of w100bp, spanning eight exons, to call variant at an expected mean coverage of 1000x. Variants called by the Ion Reporter Server were manually filtered by allele frequency >¼ 0.05 and at least 10 supporting reads, discarding synonymous substitutions and homozygous reference genotypes. Variants were annotated against COSMIC, dbSNP and ExAC databases to classify them in known or novel variants. Functional impact algorithms SIFT and PolyPhen were used. Clinical information was gathered on a GCP-compliant setup and monitored 100% on-site. Prevalence is reported within 95% CI, and associations with clinical characteristics are evaluated by Chi-Squared test or ANOVA, as appropriate (p<0.05). Results: We found that 214 out of 821 subjects, or 26.06% (95% CI: 23.15% to 29.14%) of the studied population, harbor an EGFR mutation. Among known variants, exon 19 E746_A750 deletion (COSM13243) and exon 18 A698T (COSM41905) were the most abundant variations. Non-smokers and under 45 years old subjects were more likely to have a relevant EGFR mutation (p<0.01), in agreement with the literature. Gender did not correlate significantly as a predictor of EGFR mutations (p>0.15) in the cohort analyzed. Conclusion: We expect these results shed light into the Chilean molecular epidemiology and supports initiatives to establish new diagnosis methods and treatment opportunities for Chilean cancer patients.
Background: Endoscopic operations on trachea and bronchi are palliative method of lung cancer common forms treatment. The use of this surgical interventions type in patients with the above pathology improves quality and extends the life span. We summarized the 30-year experience of performing endobronchial operations in patients with lung cancer. Method: In the clinic, endoscopic operations on the trachea and bronchi in lung cancer were performed in 1,720 patients, of which 1384 were men and 336 women. Total number of operations 4781. All patients had complete or partial stenosis of bronchi and trachea. Radical surgery was impossible to perform due to the prevalence of the process, either because of the comorbidity presence. Basically, we used a rigorous Friedel bronchoscope -in 1255 patients, the remaining 465 patients used an Olympus fibrobronchoscope. Rigid bronchoscopy was performed using endotracheal anesthesia, interventions with the use of a fibroblochoscope were performed under local anesthesia. We used three methods of influencing the tumor: laser radiation (1259 patients), electrosurgical method (146 patients) and radiofrequency ablation (315 patients). As a source of laser radiation, we used YAG-Nd laser, with a wavelength of 1064 nm and a power of 40 W. Both contact and non-contact methods of influencing the tumor were used. Electrosurgical operations implemented by a contact method using a conventional surgical coagulator under local anesthesia using fibrobronchoscope. The radiofrequency ablation (RFA) method implies the use of an electron wave at a frequency of 500 kHz. As a power source was used Fotec 150 generator. Operative interventions were performed under local anesthesia with the use of fibrobronchoscopy method. Results: In all 1720 patients we managed to achieve complete or partial trachea and bronchi recanalization. The best results were obtained in patients using the RFA method, complete recanalization was achieved in 85% of patients. The diathermocoagulation method showed significantly lower efficiency (complete patency was restored in 24% of patients) and in 28 patients of this group developed pulmonary hemorrhage, which could not be stopped in 8 patients. The use of the YAG-Nd laser made it possible to restore bronchial patency completely in 64% of patients. Conclusion: 1. Endoscopic surgery for tumor stenosis of the respiratory tract are palliative, but their use can improve the quality of life and prolong the life of patients. 2. The RFA method for respiratory tract tumor stenoses recanalization is an effective, simple to implement and can be used in patients with severe comorbidities. Keyword: endoscopic operations, lung cancer, palliative treatment Background: CNS metastases are known complications of advanced EGFR mutation-positive NSCLC, thus, LUX-Lung (LL) trials investigating afatinib allowed enrolment of patients with brain metastases (BM). LL3, 6 and 7 previously demonstrated activity of afatinib in patients with BM, with the magnitude of progression-free survival (PFS) improv...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.